Avoid common mistakes on your manuscript.
1 Erratum to: Am J Cardiovasc Drugs DOI 10.1007/s40256-015-0156-x
Errors have subsequently been identified in the original publication, and the following corrections should be noted:
Abstract, Results section, lines 9–11 which previously read:
After 8 weeks of double-blind treatment, the changes in msDBP were −9.50 (8.46) mmHg in the OM/AML/HCTZ group and −4.23 (7.41) mmHg in the OM/HCTZ group (both p < 0.0001 vs. baseline; p < 0.0001 between groups).
Should read:
After 8 weeks of double-blind treatment, the changes in msDBP were −11.39 (8.34) mmHg in the OM/AML/HCTZ group and −5.74 (9.22) mmHg in the OM/HCTZ group (both p < 0.0001 vs. baseline; p < 0.0001 between groups).
Results, Section 3.2 Efficacy, para 1, lines 2–3 which previously read:
After 8 weeks of double-blind treatment, the changes in msDBP were −9.50 (8.46) mmHg in the OM/AML/HCTZ group and −4.23 (7.41) mmHg in the OM/HCTZ group (both p < 0.0001 vs. baseline; p < 0.0001 between groups; Fig. 2a).
Should read:
After 8 weeks of double-blind treatment, the changes in msDBP were −11.39 (8.34) mmHg in the OM/AML/HCTZ group and −5.74 (9.22) mmHg in the OM/HCTZ group (both p < 0.0001 vs. baseline; p < 0.0001 between groups; Fig. 2a).
Results, Section 3.2 Efficacy, para 2, lines 2–5 which previously read:
The changes in msDBP and msSBP from randomization to after 4 weeks of treatment were −11.39 (8.34) mmHg and −14.75 (12.50) mmHg, respectively, in the OM/AML/HCTZ group (both p < 0.0001 vs. baseline) and −5.74 (9.22) mmHg and −7.93 (11.99) mmHg, respectively, in the OM/HCTZ group (both p < 0.0001 vs. baseline; both p < 0.0001 between groups; Fig. 2).
Should read:
…The changes in msDBP and msSBP from randomization to after 4 weeks of treatment were −9.50 (8.46) mmHg and −14.75 (12.50) mmHg, respectively, in the OM/AML/HCTZ group (both p < 0.0001 vs. baseline) and −4.23 (7.41) mmHg and −7.93 (11.99) mmHg, respectively, in the OM/HCTZ group (both p < 0.0001 vs. baseline; both p < 0.0001 between groups; Fig. 2).
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40256-015-0156-x.
Rights and permissions
About this article
Cite this article
Sohn, I.S., Kim, CJ., Oh, BH. et al. Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. Am J Cardiovasc Drugs 16, 139 (2016). https://doi.org/10.1007/s40256-016-0167-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40256-016-0167-2